Intermediate Risk Prostate Cancer: Felix Feng, MD

Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses the intermediate risk prostate cancer stratification challenge and the utility of genomics in this setting